ARTL•benzinga•
EXCLUSIVE: Artelo Biosciences Concludes First Cohort Of Healthy Volunteers Of FABP Inhibitor Program
Summary
Artelo Biosciences advances its pipeline with ART26.12 for neuropathic pain and ART27.13 for cancer-related anorexia, targeting 2025 milestones.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 13, 2025 by benzinga